Citius Oncology (NASDAQ:CTOR) Shares Up 39.8% – Here’s Why

Citius Oncology, Inc. (NASDAQ:CTOR) traded up 39.8% during mid-day trading on Monday . The stock traded as high as $1.17 and last traded at $0.93. 70,080,356 shares were traded during mid-day trading, an increase of 5,249% from the average session volume of 1,310,223 shares. The stock had previously closed at $0.67.

Citius Oncology Price Performance

The company has a quick ratio of 0.08, a current ratio of 0.34 and a debt-to-equity ratio of 0.08. The company’s 50 day moving average price is $1.04 and its 200-day moving average price is $1.14.

Citius Oncology (NASDAQ:CTOR) last issued its quarterly earnings data on Friday, February 14th. The company reported ($0.09) earnings per share (EPS) for the quarter.

Institutional Trading of Citius Oncology

An institutional investor recently raised its position in Citius Oncology stock. IFP Advisors Inc grew its holdings in shares of Citius Oncology, Inc. (NASDAQ:CTOR) by 173.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,215 shares of the company’s stock after purchasing an additional 14,080 shares during the quarter. IFP Advisors Inc’s holdings in Citius Oncology were worth $26,000 at the end of the most recent reporting period. 70.52% of the stock is owned by institutional investors and hedge funds.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.